PLATELET-AGGREGATION INHIBITING AND ANTIC OAGULANT EFFECTS OLIGOAMINES .30. ABSORPTION, ORGAN DISTRIBUTION, AND EXCRETION OF THE OLIGOAMINE-IODO-4-METHOXYPHENYL)-BUTYLAMINO]-BUTANE-2,3-DIOL AND ITS METABOLITES())

The pharmacokinetic behaviour of the 131-iodine-labelled title compoun d 3 and its metabolites in mice was investigated. A two phase, 1st or der elimination profile was observed. The second phase is very slow le aving about 35 % of radioactivity in the mice even 100 h after iv. inj ection, because of high affinity to liver and spleen, caused by strong binding of oligoamines to phospholipids of liver and blood cell membr anes. The blood-brain-barrier is not passed. No deep compartments were observed. The doses necessary for antithrombotic effects in vivo were calculated from the blood levels to be 20.5-39.7 mu mol/kg for a time interval of 1-6 h after administration.